Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 10/2017

01-10-2017 | Original Article

A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting

Authors: Andrea Vergallo, Cecilia Carlesi, Cristina Pagni, Filippo Sean Giorgi, Filippo Baldacci, Lucia Petrozzi, Roberto Ceravolo, Gloria Tognoni, Gabriele Siciliano, Ubaldo Bonuccelli

Published in: Neurological Sciences | Issue 10/2017

Login to get access

Abstract

Abnormal levels of beta amyloid (Aβ42) and tau protein concentrations in the cerebral spinal fluid (CSF) have been largely described in Alzheimer’s disease (AD). Thus, CSF analysis of these biomarkers has been incorporated in recent AD diagnostic criteria, and it is increasingly performed for neurodegenerative dementia diagnostic workout in clinical setting. Nevertheless, the precise biomarkers CSF features in neurodegenerative dementia, either AD or Frontotemporal dementia (FTD), are still not fully clear today. This is mainly due to lack of CSF clear cutoff values due to a well-known intersite (but even intrasite) variability of CSF procedures, ranging from collection to analysis. Applying CSF biomarker ratios, rather than their single values could represent a useful tool, especially for the differential diagnosis of different forms of dementia. We explored clinical values of six CSF ratios (by combining Aβ42 and tau) in order to better discriminate between AD and FTD; we identified Aβ42/p-Tau181 ratio as a potential good candidate for helping differentiating AD from FTD in the clinical practice.
Literature
1.
Ewers M, Mattsson N, Minthon L et al (2015) CSF biomarkers for the differential diagnosis of Alzheimer's disease: a large-scale international multicenter study. Alzheimers Dement 11:1306–1315CrossRefPubMed
2.
Clark CM, Xie S, Chittams J et al (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003(60):1696–1702CrossRef
3.
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269CrossRefPubMedPubMedCentral
4.
Dubois B, Feldman HH, Jacova C (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13:614–629CrossRefPubMed
5.
Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554CrossRefPubMed
6.
Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477CrossRefPubMedPubMedCentral
7.
Oeckl P, Steinacker P, Feneberg E et al (2015) Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: current status and future perspectives. Biochim Biophys Acta 1854:757–768CrossRefPubMed
8.
Irwin DJ, Trojanowski J, Grossman M (2013) Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci 5:6CrossRefPubMedPubMedCentral
9.
Sjögren M, Minthon L, Davidsson P et al (2000) CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) 107:563–579CrossRef
10.
Bian H, Van Swieten JC, Leight S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70(19 Pt 2):1827–1835CrossRefPubMedPubMedCentral
11.
Skillbäck T, Farahmand BY, Rosén C et al (2015) Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain 138:2716–2731CrossRefPubMed
12.
Erten-Lyons D, Woltjer R, Kaye J et al (2013) Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 81:977–983CrossRefPubMedPubMedCentral
13.
Claus JJ, Staekenborg SS, Roorda JJ et al (2016) Low prevalence of mixed dementia in a cohort of 2,000 elderly patients in a memory clinic setting. J Alzheimers Dis 50:797–806CrossRefPubMed
14.
Lee S, Viqar F, Zimmerman ME (2016) White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol 79:929–939CrossRefPubMedPubMedCentral
15.
Wahlund LO, Barkhof F, Fazekas F et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318–1322CrossRefPubMed
16.
Palmqvist S, Zetterberg H, Mattsson N et al (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85:1240–1249CrossRefPubMedPubMedCentral
17.
Lebedeva E, Stingl JC, Thal DR et al (2012) Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD. Neurobiol Aging 33:201CrossRefPubMed
18.
Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234CrossRefPubMed
19.
Santangelo R, Coppi E, Ferrari L et al (2015) Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia. J Alzheimers Dis 43:1429–1440PubMed
20.
Braak H, Thal DR, Ghebremedhin E et al (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969CrossRefPubMed
21.
Sutphen CL, Jasielec MS, Shah AR et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72:1029–1042CrossRefPubMedPubMedCentral
22.
Hasegawa M (2016) Molecular mechanisms in the pathogenesis of Alzheimer's disease and Tauopathies-prion-like seeded aggregation and phosphorylation. Biomol Ther 28:6
23.
Teunissen CE, Elias N, Koel-Simmelink MJ et al (2016) Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst) 2:86–94
24.
25.
Borroni B, Benussi A, Archetti S et al (2015) Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener 16:86–91CrossRefPubMed
26.
Hellwig K, Kvartsberg H, Portelius E et al (2015) Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Ther 7:74CrossRefPubMedPubMedCentral
27.
Baldacci F, Lista S, Cavedo E et al (2017) Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Rev Proteomics 14:285–299CrossRefPubMed
28.
Lista S, Hampel H (2017) Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. Expert Rev Neurother 17:47–57CrossRefPubMed
29.
Molinuevo JL, Blennow K, Dubois B et al (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement 10:808–817CrossRefPubMed
30.
Balasa M, Sánchez-Valle R, Antonell A et al (2014) Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. J Alzheimers Dis 40:919–927PubMed
Metadata
Title
A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting
Authors
Andrea Vergallo
Cecilia Carlesi
Cristina Pagni
Filippo Sean Giorgi
Filippo Baldacci
Lucia Petrozzi
Roberto Ceravolo
Gloria Tognoni
Gabriele Siciliano
Ubaldo Bonuccelli
Publication date
01-10-2017
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 10/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-017-3053-z

Other articles of this Issue 10/2017

Neurological Sciences 10/2017 Go to the issue

Original Article

Glial and neuronal antibodies in patients with idiopathic intracranial hypertension

Letter to the Editor

The added value of combined visual and semi-quantitative assessment for 123I-FP-CIT SPECT and reply to Ueda et al.

Letter to the Editor

Dissecating aneurysm of extracranial internal carotid artery presenting with Tapia syndrome in patient with essential thrombocythemia

Original Article

The effect of different ankle and knee supports on balance in early ambulation of post-stroke hemiplegic patients

Original Article

Is CT perfusion helpful in the treatment allocation of patients with acute ischemic stroke? An expert-opinion analysis

Original Article

Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting